Moderna (MRNA) Non-Current Deffered Revenue (2017 - 2026)

Moderna (MRNA) has 10 years of Non-Current Deffered Revenue data on file, last reported at $154.0 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $154.0 million, up 165.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.0 million (up 165.52% YoY), and the FY2025 annual result was $153.0 million, up 163.79% from the prior year.
• Non-Current Deffered Revenue grew to $154.0 million in Q1 2026 per MRNA's latest filing, from $153.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $692.0 million in Q2 2023 and troughed at $58.0 million in Q1 2024.
• A 5-year average of $248.5 million and a median of $154.0 million in 2026 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2024 and 2026: Non-Current Deffered Revenue tumbled 91.38% in 2024, then jumped 165.52% in 2026.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $673.0 million in 2022, then sank by 87.67% to $83.0 million in 2023, then slumped by 30.12% to $58.0 million in 2024, then soared by 163.79% to $153.0 million in 2025, then rose by 0.65% to $154.0 million in 2026.
• Business Quant data shows MRNA's Non-Current Deffered Revenue at $154.0 million in Q1 2026, $153.0 million in Q4 2025, and $157.0 million in Q3 2025.